Literature DB >> 23810753

[Benzodiazepine dependence and the risk of depression and anxiety disorders: seniors' health study].

P-G Nkogho Mengue1, B Abdous2, D Berbiche3, M Preville3, P Voyer4.   

Abstract

AIM OF THE STUDY: The objective of this study is to examine the relationship between benzodiazepine dependence and anxiety disorders and depression in people aged 65 years and over. We referred to the data from the study on the health of seniors, a survey of a representative sample of 707 benzodiazepine users living in the community in Quebec, Canada. Benzodiazepine dependence, anxiety disorders and depression were measured using self-reported questionnaires based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth revised edition.
RESULTS: Seniors have consumed an average daily dose of 6.1±7.6mg diazepam equivalent to an average of 205±130 days. The prevalence of benzodiazepine dependence has been estimated at 9.5%. This dependence increases the risk of minor depression for females (relative risk [RR]=4.36, confidence interval 95% [95% CI]=1.19 to 15.99).
CONCLUSION: The results of this study suggest that the use of benzodiazepines is far from being optimal among seniors in Quebec. The proportion of seniors who develop an addiction is important. The results illustrate the need to develop and implement programs to improve the quality of benzodiazepine use among this population.
Copyright © 2013 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anxiety disorders; Benzodiazepine dependence; Depression; Dépendance aux benzodiazépines; Dépression; Personnes aînées; Quebec; Québec; Seniors; Troubles anxieux

Mesh:

Substances:

Year:  2013        PMID: 23810753     DOI: 10.1016/j.encep.2013.04.011

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  1 in total

Review 1.  Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.

Authors:  Philippe Yves Rémy Simon; Pierre-François Rousseau
Journal:  Can J Psychiatry       Date:  2016-07-19       Impact factor: 4.356

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.